Protagenic Therapeutics, Inc.\new SEC filings PTIX
Protagenic Therapeutics, Inc.\new has 705 filings in SEC EDGAR's recent list, going back to Oct 22, 1996. Its latest annual report, Form 10-K, was filed on Aug 14, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 19, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 20, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Dec 5, 2025 | Dec 5, 2025 |
| DEFA14A | Additional proxy material | May 19, 2025 | — |
| DEF 14A | Proxy statement | Mar 10, 2025 | Mar 7, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 27, 2025 | Feb 26, 2025 |
| DEFA14A | Additional proxy material | Jan 6, 2025 | — |
| DEF 14A | Proxy statement | Jan 3, 2025 | Jan 3, 2025 |
| PRE 14A | Preliminary proxy statement | Dec 19, 2024 | Dec 18, 2024 |
| DEF 14A | Proxy statement | Nov 2, 2023 | Nov 2, 2023 |
| DEF 14A | Proxy statement | Oct 12, 2022 | Oct 11, 2022 |
| DEF 14A | Proxy statement | Sep 8, 2021 | Sep 8, 2021 |
| DEF 14A | Proxy statement | Aug 28, 2020 | Aug 28, 2020 |
| DEFA14A | Additional proxy material | Aug 26, 2019 | — |
| DEF 14A | Proxy statement | Aug 12, 2019 | Aug 12, 2019 |
| DEFA14A | Additional proxy material | Jun 13, 2018 | — |
| DEF 14A | Proxy statement | Jun 13, 2018 | Jun 13, 2018 |
| DEF 14A | Proxy statement | May 26, 2017 | Jul 7, 2017 |
| DEF 14A | Proxy statement | May 3, 2016 | Jun 17, 2016 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2016 | Apr 20, 2016 |
| PRE 14A | Preliminary proxy statement | Sep 15, 2011 | Sep 15, 2011 |
| DEFA14A | Additional proxy material | Dec 7, 2010 | — |
| DEFA14A | Additional proxy material | Nov 19, 2010 | — |
| DEF 14A | Proxy statement | Oct 25, 2010 | Dec 1, 2010 |
| DEFA14A | Additional proxy material | Oct 14, 2010 | — |
| PRE 14A | Preliminary proxy statement | Oct 4, 2010 | Oct 4, 2010 |
| DEF 14A | Proxy statement | May 26, 2009 | Jun 25, 2009 |
| PRE 14A | Preliminary proxy statement | Apr 30, 2009 | Apr 30, 2009 |
| PRE 14A | Preliminary proxy statement | Nov 26, 2008 | Jan 7, 2009 |
| DEF 14C | Information statement | Apr 2, 2007 | Mar 30, 2007 |
| PRE 14C | Filing | Mar 19, 2007 | Mar 15, 2007 |
| DEF 14A | Proxy statement | Mar 10, 2003 | Mar 25, 2003 |
| DEF 14A | Proxy statement | Oct 31, 2001 | Nov 19, 2001 |
| DEF 14A | Proxy statement | Nov 6, 2000 | Nov 30, 2000 |
| DEF 14A | Proxy statement | Nov 3, 1999 | Nov 30, 1999 |
| DEF 14A | Proxy statement | Nov 3, 1998 | Nov 20, 1998 |
| DEF 14A | Proxy statement | Nov 12, 1997 | Dec 10, 1997 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTIX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1022899
- Former names
- Atrinsic, Inc. (until Jun 20, 2016); NEW MOTION, INC. (until Jun 30, 2009); MPLC, Inc. (until Apr 2, 2007); MILLBROOK PRESS INC (until May 23, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.